This clinical reference investigates the application of dopamine agonist therapy as a neuroendocrine-based treatment for Type 2 diabetes. Authored by Vivian Fonseca, the text addresses the limitations of traditional peripheral-acting glucose regulators by introducing a mechanism that targets insulin resistance through neuroendocrine pathways. It serves as a concise clinical guide for practitioners seeking to integrate this novel pharmacological approach into standard diabetes management protocols.

Medical professionals utilize this text as a quick-reference tool for navigating the specific administration protocols of newer diabetes therapies. Experts highlight the utility of this pocket card for clinicians who require immediate, evidence-based guidance in a high-volume clinical setting.